BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.